UBS Group’s Freeline Therapeutics Holdings plc American Depositary Shares FRLN Stock Holding History

UBS Group’s Portfolio FRLN Stock Details FRLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-99,358	Closed	-$633K	–	10376
2023 Q4	$633K	Buy	99,358 +65,154	+190%	+$349K	﹤0.01%	4899
2023 Q3	$147K	Buy	34,204 +871	+3%	+$3.44K	﹤0.01%	5585
2023 Q2	$86K	Hold	33,333	–	–	﹤0.01%	6134
2023 Q1	$228K	Sell	33,333 -1,129	-3%	-$8.76K	﹤0.01%	5289
2022 Q4	$248K	Buy	34,462 +49	+0.1%	+$467	﹤0.01%	5286
2022 Q3	$361K	Buy	34,413 +777	+2%	+$10.1K	﹤0.01%	4620
2022 Q2	$439K	Sell	33,636 -12	-0%	-$154	﹤0.01%	4354
2022 Q1	$565K	Buy	+33,648	New	+$624K	﹤0.01%	4597
2021 Q4	–	Sell	-33	Closed	-$2K	–	10923
2021 Q3	$2K	Buy	+33	New	+$2.35K	﹤0.01%	9025

UBS Group's FRLN Position: Q1 2024 in Review

UBS Group sold out of Freeline Therapeutics Holdings plc American Depositary Shares (FRLN) in Q1 2024, closing a stake of 99,358 shares — an estimated $633K sold.

UBS Group first reported a position in FRLN in Q3 2021 and held it in 9 quarters. The position peaked at $633K in Q4 2023. 0 funds tracked by Wall St. Rank hold FRLN as of Q1 2024.

UBS Group reported no remaining Freeline Therapeutics Holdings plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
UBS Group sold 99,358 Freeline Therapeutics Holdings plc American Depositary Shares shares in Q1 2024, an estimated $633K.
UBS Group first reported a position in Freeline Therapeutics Holdings plc American Depositary Shares in Q3 2021 and held it in 9 quarters.
UBS Group's Freeline Therapeutics Holdings plc American Depositary Shares position peaked at $633K in Q4 2023.
0 funds tracked by Wall St. Rank held Freeline Therapeutics Holdings plc American Depositary Shares as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.